{
    "address": "Erik Dahlbergsgatan 11A",
    "city": "Goeteborg",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W1R97M109",
    "description": "Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-11-25. The firm is engaged in the discovery and development of therapeutics for the treatment of Alzheimer\u2019s disease. The firm focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric A\u03b2 that damages brain synapses.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2015-11-25",
    "isin": "SE0007413455",
    "logo": "",
    "marketCapitalization": 129.2032,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Alzinova AB",
    "phone": "46704282656.0",
    "sedol": "BYMFTM5",
    "shareOutstanding": 15.775724,
    "state": "VASTRA GOTALANDS",
    "ticker": "ALZ.ST",
    "weburl": "http://www.alzinova.com/"
}